0000010795-23-000038.txt : 20230504 0000010795-23-000038.hdr.sgml : 20230504 20230504063646 ACCESSION NUMBER: 0000010795-23-000038 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230504 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230504 DATE AS OF CHANGE: 20230504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BECTON DICKINSON & CO CENTRAL INDEX KEY: 0000010795 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 220760120 STATE OF INCORPORATION: NJ FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-04802 FILM NUMBER: 23886304 BUSINESS ADDRESS: STREET 1: ONE BECTON DR CITY: FRANKLIN LAKES STATE: NJ ZIP: 07417-1880 BUSINESS PHONE: 2018476800 MAIL ADDRESS: STREET 1: ONE BECTON DR CITY: FRANKLIN LAKE STATE: NJ ZIP: 07417 8-K 1 bdx-20230504.htm 8-K bdx-20230504
0000010795false00000107952023-05-042023-05-040000010795us-gaap:CommonStockMemberexch:XNYS2023-05-042023-05-040000010795exch:XNYSus-gaap:RedeemablePreferredStockMember2023-05-042023-05-040000010795bdx:Notes1.900dueDecember152026Memberexch:XNYS2023-05-042023-05-040000010795exch:XNYSbdx:Notes1.401dueMay242023Member2023-05-042023-05-040000010795bdx:Notes3.020dueMay242025Memberexch:XNYS2023-05-042023-05-040000010795bdx:Notes0.632dueJune42023Memberexch:XNYS2023-05-042023-05-040000010795bdx:Notes1.208dueJune42026Memberexch:XNYS2023-05-042023-05-040000010795exch:XNYSbdx:Notes1213DueFebruary122036Member2023-05-042023-05-040000010795exch:XNYSbdx:Notes0000DueAugust132023Member2023-05-042023-05-040000010795exch:XNYSbdx:Notes0034DueAugust132025Member2023-05-042023-05-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) May 4, 2023
BECTON, DICKINSON AND COMPANY
(Exact Name of Registrant as Specified in Its Charter)
New Jersey
(State or Other Jurisdiction of Incorporation)
001-4802 22-0760120
(Commission File Number) (IRS Employer Identification No.)
  
1 Becton Drive, Franklin Lakes,
New Jersey
 07417-1880
(Address of Principal Executive Offices) (Zip Code)
(201) 
847-6800
 (Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:


Title of Each ClassTrading Symbol
Name of each exchange on
which registered
Common stock, par value $1.00BDXNew York Stock Exchange
Depositary Shares, each representing a 1/20th interest in a share of 6.00% Mandatory Convertible Preferred Stock, Series BBDXBNew York Stock Exchange
1.900% Notes due December 15, 2026BDX26New York Stock Exchange
1.401% Notes due May 24, 2023BDX23ANew York Stock Exchange
3.020% Notes due May 24, 2025BDX25New York Stock Exchange
0.632% Notes due June 4, 2023BDX/23ANew York Stock Exchange
1.208% Notes due June 4, 2026BDX/26ANew York Stock Exchange
1.213% Notes due February 12, 2036BDX/36New York Stock Exchange
0.000% Notes due August 13, 2023BDX23BNew York Stock Exchange
0.034% Notes due August 13, 2025BDX25ANew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐



ITEM 2.02    RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On May 4, 2023, Becton, Dickinson and Company (“BD”) issued a press release announcing its financial results for its second fiscal quarter ending March 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (“non-GAAP measures”). Details regarding these non-GAAP measures and adjustments can be found in the schedules included in the press release furnished as Exhibit 99.1.
















ITEM 9.01    FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit 99.1     Press release dated May 4, 2023, which is furnished pursuant to Item 2.02.

Exhibit 104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)
By:/s/ Gary DeFazio
 Gary DeFazio
 Senior Vice President and Corporate Secretary
Date: May 4, 2023

EX-99.1 2 ex99103312023.htm EX-99.1 Document

Exhibit 99.1

1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com



imagea.jpg



Contacts:
Investors: Francesca DeMartino, SVP, Head of Investor Relations - 201-847-5743
Media: Troy Kirkpatrick, VP, Public Relations - 858-617-2361

BD Reports Second Quarter Fiscal 2023 Financial Results

BD 2025 Strategic Investments Driving Growth and Advancing Innovation; Company Raises Mid-point of Revenue and Adjusted EPS Guidance Ranges

•Revenue of $4.8 billion increased 1.5% as reported and 4.1% on a currency-neutral basis
•Revenue from base business (which excludes COVID-only diagnostic testing) grew 6.0% as reported, 8.7% currency-neutral
•GAAP and adjusted diluted EPS from continuing operations of $1.53 and $2.86, respectively
•Company raises full-year base revenue guidance, enabling additional investments in growth and innovation while absorbing lower COVID-only diagnostic testing revenue and incremental FX impacts

FRANKLIN LAKES, NJ (May 4, 2023) - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its second quarter of fiscal 2023, which ended March 31, 2023.

“Since launching BD 2025, we have made purposeful and strategic investments to shift BD into attractive end markets to advance innovations that are transforming healthcare and driving company growth,” said Tom Polen, chairman, CEO and president of BD. “Our strong performance this quarter reflects our strategy in action and the positive impact of these investments on our business as we deliver for our customers and patients around the world. Particularly, our innovation pipeline and the impact of our M&A strategy played a key role in our results, and we remain well-positioned to continue driving strong growth and performance in the future.”

Recent Business and ESG Highlights

•In BD Life Sciences, the Biosciences business unit completed the first early access shipments to customers of the BD FACSDiscover™ S8 Cell Sorter, the worlds' first real-time imaging, spectral flow cytometer equipped with the breakthrough BD CellView™ Image Technology profiled last year on the cover of the journal Science.
•In BD Life Sciences, the Biosciences business unit introduced the BD Rhapsody™ HT Xpress System, a new high-throughput single-cell multiomics platform that enables scientists to isolate, barcode and analyze single cells at a high sample throughput to obtain more insights in less time. The new system, alongside BD cell sorters and the rest of the BD Rhapsody™ portfolio of reagents, assays and bioinformatics tools, enables BD to provide a true end-to-end portfolio of single-cell multiomics solutions for researchers.
Page 1

•In BD Life Sciences, the Integrated Diagnostics Solutions business unit received FDA approval for the BD Onclarity™ HPV molecular diagnostics assay for use with both BD SurePath™ liquid-based pap test and Hologic ThinPrep® pap test. Approval expands access to the BD HPV test - the only FDA-approved assay that tests for an extended set of HPV types individually, and particularly for HPV31, a specific type of HPV that poses a high-risk for causing cervical cancer.
•In BD Life Sciences, the Integrated Diagnostics Solutions business unit received FDA 510(k) clearance for the BD Vaginal Panel for use on the BD COR™ System. This first-of-its-kind, high-throughput molecular diagnostic test for large laboratories directly detects the three most common infectious causes of vaginitis using only one swab and one test. Availability of the vaginal panel reflects BD's commitment to expand the menu of assays for women's health and other infectious diseases.
•In BD Life Sciences, the Integrated Diagnostics Solutions business unit filed for US regulatory clearance of BD MiniDraw™, a device which enables the collection of a high-quality capillary blood sample that is less invasive and more convenient than the traditional collection method.
•In BD Medical, the Medication Delivery Solutions business unit launched the BD Prevue™ II System, the latest example of how BD is advancing the vision of a "one-stick hospital stay" with new ultrasound technology that helps drive first-stick success for IV insertions.
•BD continued to further its progress toward achieving its 2030+ ESG goals, including its focus on reducing the environmental impact of its product portfolio. To support this effort, BD introduced new circular economy pilots in several regions, partnering with healthcare facilities and waste management companies to recycle used materials, including BD syringes in the US and BD vacutainers in Denmark.

Basis of Presentation— Continuing Operations

On April 1, 2022, the Company completed the spin-off of its Diabetes Care business as a separate publicly traded company named Embecta Corp. (“Embecta”). The historical results of the Diabetes Care business are now accounted for as discontinued operations. Financial information presented in this release reflects BD’s results on a continuing operations basis, which excludes Embecta. The prior periods have been recast to conform to this presentation.

Second Quarter Fiscal 2023 Operating Results

 Three Months Ended March 31,Change
Foreign Currency Neutral Change1
(Millions of dollars, except per share amounts)20232022  
Revenues$4,821 $4,750 1.5 %4.1 %
Base Revenues1
$4,805 $4,535 6.0 %8.7 %
Base Organic Revenue Growth1
4.3 %7.0 %
Reported Diluted Earnings per Share$1.53 $1.28 19.5 %36.7 %
Adjusted Diluted Earnings per Share1
$2.86 $2.78 2.9 %11.2 %

1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in the attached financial tables. Base revenues denotes total revenues less estimated revenues for COVID-19-only diagnostic testing. Base Organic Revenue Growth further excludes the contribution from inorganic revenues from acquisitions, which is defined as revenues recognized during the first 12 months post-acquisition.


Page 2

Geographic Results

Revenues (Millions of dollars)
Three Months Ended March 31, Reported Change 
Foreign Currency Neutral Change1
20232022
United States$2,733 $2,669 2.4 %2.4 %
International$2,088 $2,081 0.4 %6.3 %
Total Revenues$4,821 $4,750 1.5 %4.1 %

1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in the attached financial tables.

Segment Results

Revenues (Millions of dollars)
Three Months Ended March 31,Reported Change
Foreign Currency Neutral Change1
Reported Change Base Revenues1
Foreign Currency Neutral Change Base Revenues1
20232022
BD Medical  $2,360 $2,154 9.6 %12.2 %9.6 %12.2 %
BD Life Sciences  $1,275 $1,485 (14.2)%(11.5)%(0.9)%2.2 %
BD Interventional$1,186 $1,111 6.8 %9.3 %6.8 %9.3 %
Total Revenues$4,821 $4,750 1.5 %4.1 %6.0 %8.7 %

1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in the attached financial tables. Base revenues denotes total revenues less estimated revenues for COVID-19-only diagnostic testing.

The BD Medical segment includes the Medication Delivery Solutions (MDS), Medication Management Solutions (MMS), and Pharmaceutical Systems (PS) business units. BD Medical revenue growth was driven by strong double-digit growth in MMS and PS.
•MDS performance reflects our comprehensive Vascular Access Management strategy that continues to drive strong results, evidenced by BD Posiflush™ and our Catheter Solutions. Strength in our durable core products more than offset the comparison to prior-year COVID vaccine device demand and planned strategic portfolio exits.
•MMS performance reflects investments in high-growth end-markets, such as Pharmacy Automation, which are driving strong performance, led by our Parata and BD ROWA™ solutions. MMS performance also reflects double-digit growth in Dispensing driven by our continued focus on innovation to improve workflows and efficiencies, evidenced by performance of our BD Pyxis™ and BD HealthSight™ portfolio including the recent BD Pyxis™ ES 1.7 launch.
•PS performance reflects another strong quarter enabled by capacity investments in BD Hypak™ and innovation in products like BD Effivax™, BD Hylok™ and BD Neopak™, which are enhancing efficiencies for our Pharmaceutical customers while supporting increased demand in the high-growth biologics and vaccine categories.
The BD Life Sciences segment includes the Integrated Diagnostic Solutions (IDS) and Biosciences (BDB) business units. BD Life Sciences performance reflects growth in the segment's base business despite a negative impact of approximately 800 basis points from the comparison to prior-year respiratory testing revenues. The segment's performance also reflects a decline in COVID-only diagnostic testing revenues.
•IDS performance reflects the decline in COVID-only diagnostic testing revenues as well as the impact in the base business from the comparison to higher prior-year combination flu/COVID respiratory testing revenues and due to a softer respiratory illness season in the current quarter. Partially offsetting the decline in combination testing was growth in Microbiology, aided by adoption of our BD Kiestra™ IdentifA and Total Modular Track solutions, and Specimen Management, and continued double-digit growth from Molecular IVD assays leveraging the incremental BD Max™ installed base.
Page 3

•BDB performance reflects continued double-digit growth in Research Reagents enabled by our innovative and differentiated BD Horizon™ dyes. Strong performance in Instruments was driven by continued demand for the recently launched BD FACSymphony™ A1/A5 SE research analyzers combined with improved BD FACSLyric™ product availability for our clinical customers.
The BD Interventional segment includes the Surgery, Peripheral Intervention (PI), and Urology & Critical Care (UCC) business units. BD Interventional performance was driven by strong performance across the segment.
•Surgery performance reflects double-digit worldwide growth in Advanced Repair and Reconstruction, driven by continued market adoption of the Phasix™ hernia resorbable scaffold and double-digit worldwide growth in Biosurgery, aided by Arista™ AH absorbable hemostat. Strong procedure volumes also contributed to Surgery performance.
•PI performance reflects double-digit growth in Peripheral Vascular Disease driven by the Venovo™ relaunch, coupled with global penetration of Rotarex™. PI performance also reflects strong growth in Oncology in the US and Greater Asia that was aided by an improved backlog associated with prior-year supplier constraints.
•UCC performance reflects double-digit growth in the PureWick™ franchise, aided by the recent launch of PureWick™ Male, with a strong presence in both the acute care and alternative care settings for chronic incontinence. UCC performance also reflects double-digit growth in Endourology that benefited from improved supplier performance.

Assumptions and Outlook for Full Year Fiscal 2023

The company raised the lower-end and mid-point of its full-year revenue and adjusted EPS guidance ranges. This includes an increase to base business currency-neutral revenue growth, which is enabling additional investments in growth and innovation while absorbing lower COVID-only diagnostic testing revenue and an estimated incremental foreign currency headwind.

•The company now expects fiscal year 2023 revenues to be in the range of approximately $19.2 billion to $19.3 billion compared to $19.1 billion to $19.3 billion previously announced, which reflects an increase of approximately $50 million at the mid-point.
•Revenue guidance now assumes base business currency-neutral revenue growth of 6.5% to 7.0% compared to 5.75% to 6.75% previously announced, which represents an increase of 50 basis points, or approximately $90 million at the mid-point.
•Revenue guidance now assumes approximately $50 million in COVID-only diagnostic testing revenues, compared to approximately $50 million to $100 million previously announced.
•Based on current rates, foreign exchange continues to represent a reduction of approximately 200 basis points, or approximately $370 million, to total company revenue growth.
•The company now expects fiscal year 2023 adjusted diluted EPS to be $12.10 to $12.32 compared to $12.07 to $12.32 previously announced. This reflects an increase of 1.5 cents at the mid-point, including an operational increase of 6.5 cents offset by an incremental headwind of approximately 5 cents from foreign currency.
•On a currency-neutral basis, adjusted diluted EPS guidance now represents growth of approximately 9.5% to 11%.
•Adjusted diluted EPS guidance now includes an estimated headwind from foreign currency of approximately 270 basis points based on current rates.

BD's outlook for fiscal 2023 reflects numerous assumptions about many factors that could affect its business, based on the information management has reviewed as of this date. Management will discuss its outlook and several of its assumptions on its second fiscal quarter earnings call.

The company's expected adjusted diluted EPS for fiscal 2023 excludes potential charges or gains that may be recorded during the fiscal year, such as, among other things, the non-cash amortization of intangible assets, acquisition-related charges, spin related costs, and certain tax matters. BD does not attempt to provide reconciliations of forward-looking adjusted diluted non-GAAP EPS guidance to the comparable GAAP measure because the impact and timing of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of BD’s financial performance. We also present our estimated revenue, base business revenue growth and adjusted diluted EPS growth for our 2023 fiscal year after adjusting for the anticipated impact of foreign currency translation. BD believes that this adjustment allows
Page 4

investors to better evaluate BD’s anticipated underlying earnings performance for our 2023 fiscal year in relation to our underlying 2022 fiscal year performance.

Conference Call and Presentation Materials
BD will host an audio webcast today for the public, investors, analysts, and news media to discuss its second quarter results. The audio webcast will be broadcast live on BD’s website, www.bd.com/investors at 8 a.m. (ET) Thursday, May 4, 2023. Accompanying slides will be available on BD’s website, www.bd.com/investors at approximately 6:30 a.m. (ET). The conference call will be available for replay on BD’s website, www.bd.com/investors. Alternatively, you can dial into the replay at 1-800-688-7036 (domestic) and 1-402-220-1346 (international) through the close of business on Thursday, May 11, 2023. A confirmation number is not needed to access the replay.

Non-GAAP Financial Measures/Financial Tables
This news release contains certain non-GAAP financial measures. These include revenue growth rates on a currency-neutral basis, adjusted diluted earnings per share, base revenue, base organic revenue growth and base revenue growth rates on a currency-neutral basis. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States. BD management believes that the use of non-GAAP measures to adjust for items that are considered by management to be outside of BD’s underlying operational results or that affect period to period comparability helps investors to gain a better understanding of our performance year-over-year, to analyze underlying trends in our businesses, to analyze our base operating results, and understand future prospects. Management uses these non-GAAP financial measures to measure and forecast the company’s performance, especially when comparing such results to previous periods or forecasts. We believe presenting such adjusted metrics provides investors with greater transparency to the information used by BD management for its operational decision-making and for comparison to other companies within the medical technology industry. Although BD’s management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD’s net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. BD strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by BD may differ from similar measures used by other companies, even when similar terms are used to identify such measures. Non-GAAP measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

We present adjusted diluted earnings per share for the second quarter and the first six months of fiscal year 2023, and the corresponding prior periods, after eliminating items we believe are not part of our ordinary operations and affect the comparability of the periods presented. Adjusted diluted earnings per share includes adjustments for the impact of purchase accounting adjustments, integration and restructuring costs, spin related costs, certain regulatory costs, certain product remediation costs, certain product liability and legal defense costs, certain investment gains and losses, and certain asset impairment charges. In particular, current and prior-year adjusted diluted earnings per share results exclude European regulatory initiative-related costs, which represent costs incurred to develop processes and systems to establish initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation (collectively, the “New EU Medical Devices Regulations”), which represent a significant, unusual change to the existing regulatory framework. We consider the excluded European regulatory initiative-related costs to be duplicative of previously incurred costs and/or one-off costs related to establishing initial compliance with such regulatory regimes, and in each case are limited to a specific period of time. These expenses relate to establishing initial compliance with the New EU Medical Devices Regulations and include the cost of labor, other services and consulting (in particular, research and development and clinical trials) and supplies, travel and other miscellaneous costs. These costs were recorded in Cost of products sold and Research and development expense.

We also present revenue growth rates for the second quarter and first six months of fiscal year 2023 over the corresponding prior periods on a currency-neutral basis after eliminating the effect of foreign currency translation, where applicable. We also show the growth in adjusted diluted earnings per share compared to the prior year periods after eliminating the impact of foreign currency translation to further enable investors to evaluate BD’s underlying earnings performance compared to the prior periods. We calculate foreign currency-neutral percentages by converting
Page 5

our current-period local currency financial results using the prior period foreign currency exchange rates and comparing these adjusted amounts to our current-period results. As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a foreign currency-neutral basis in addition to reported results helps improve investors’ ability to understand our operating results and evaluate our performance in comparison to prior periods.

Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying amounts.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

***

This press release contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD’s future prospects and performance, including, but not limited to, future revenues and earnings per share. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially. These factors include, but are not limited to, risks relating to the macroeconomic environment on our operations and healthcare spending, including any impact of the current disruptions in the global supply chain on our ability to source raw materials, components and energy sources needed to produce our products, labor constraints, inflationary pressures, currency rate fluctuations and increased interest rates; geopolitical developments such as the ongoing Russia and Ukraine conflict and the evolving conditions in Asia, which could adversely impact our operations; increases in energy costs and their effect on, among other things, the cost of producing BD’s products; product efficacy or safety concerns resulting in product recalls or actions being taken with respect to our products; new or changing laws and regulations impacting our business (including the imposition of tariffs, changes in tax laws, new environmental laws and regulations, new cybersecurity or privacy laws or changes in laws impacting international trade) or changes in enforcement practices with respect to such laws; increased labor costs; our suppliers’ ability to provide products needed for our operations and BD’s ability to maintain favorable supplier arrangements and relationships; legislative or regulatory changes to the U.S. or foreign healthcare systems, potential cuts in governmental healthcare spending (including China’s volume-based procurement tender process) or governmental or private measures to contain healthcare costs, including changes in pricing and reimbursement policies, each of which could result in reduced demand for our products or downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including inflation, deflation and fluctuations in interest rates and foreign exchange rates, particularly in emerging markets, including any impact on our ability to access credit markets and finance our operations; the adverse impact of cyberattacks on our information systems or products; competitive factors including technological advances and new products introduced by competitors; risks relating to our overall indebtedness; the possible impact of COVID-19, including any resurgence or new strains, on our business and the global healthcare system, which could result in decreased demand for our products, disruptions to our operations or the operations of our suppliers and customers and our supply chain, and factors such as vaccine utilization rates, infection rates, the emergence of new variants and competitive factors that could impact the demand and pricing for our COVID-19 diagnostics testing; interruptions in our manufacturing or sterilization processes or those of our third-party providers; pricing and market pressures; difficulties inherent in product development, delays in product introductions and uncertainty of market acceptance of new products; the remediation of our infusion pump business (including risks relating to our ability to obtain regulatory clearance and market acceptance of the BD Alaris™ System); our ability to achieve our projected level or mix of product sales; our ability
Page 6

to successfully integrate any businesses we acquire; uncertainties of litigation and/or investigations and/or subpoenas (as described in BD’s filings with the Securities and Exchange Commission ("SEC")); and the issuance of new or revised accounting standards, as well as other factors discussed in BD’s filings with the SEC. In addition, we have made certain assumptions in making these forward-looking statements, particularly regarding supply chain pressures, inflation and foreign exchange rates. If any of these assumptions are incorrect, BD's actual results could differ materially from those described in these forward-looking statements. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

Page 7

BECTON DICKINSON AND COMPANY
CONDENSED CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in millions, except share and per share data)

   Three Months Ended March 31,
   20232022% Change
REVENUES$4,821 $4,750 1.5 
 
Cost of products sold2,586 2,637 (2.0)
Selling and administrative expense1,205 1,192 1.0 
Research and development expense337 327 3.1 
Acquisition-related integration and restructuring expense62 28 117.4 
Other operating expense, net4 — 100.0 
TOTAL OPERATING COSTS AND EXPENSES4,193 4,185 0.2 
OPERATING INCOME628 564 11.3 
 
Interest expense(118)(97)21.1 
Interest income10 2 429.2 
Other income (expense), net8 (27)130.2 
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES529 442 19.6 
Income tax provision68 52 30.7 
NET INCOME FROM CONTINUING OPERATIONS460 390 18.2 
Income from discontinued operations, net of tax— 64 (100.0)
NET INCOME460 454 1.5 
Preferred stock dividends(23)(23)— 
NET INCOME APPLICABLE TO COMMON SHAREHOLDERS$438 $431 1.5 
 
BASIC EARNINGS PER SHARE
Income from Continuing Operations1.54 1.29 19.4 
Income from Discontinued Operations— 0.22 (100.0)
Basic Earnings per Share$1.54 $1.51 2.0 
DILUTED EARNINGS PER SHARE
Income from Continuing Operations1.53 1.28 19.5 
Income from Discontinued Operations— 0.22 (100.0)
Diluted Earnings per Share$1.53 $1.50 2.0 
 
AVERAGE SHARES OUTSTANDING (in thousands)
Basic284,292285,243
Diluted285,645287,299

Page 1

BECTON DICKINSON AND COMPANY
CONDENSED CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in millions, except share and per share data)

   Six Months Ended March 31,
 20232022% Change
REVENUES$9,407 $9,468 (0.6)
 
Cost of products sold5,038 5,135 (1.9)
Selling and administrative expense2,392 2,378 0.6 
Research and development expense651 641 1.5 
Acquisition-related integration and restructuring expense106 62 69.1 
Other operating expense (income), net7 (4)262.9 
TOTAL OPERATING COSTS AND EXPENSES8,193 8,212 (0.2)
OPERATING INCOME1,213 1,256 (3.4)
 
Interest expense(220)(195)13.0 
Interest income16 4 321.6 
Other income (expense), net1 (24)102.3 
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES1,009 1,041 (3.1)
Income tax provision40 84 (51.9)
NET INCOME FROM CONTINUING OPERATIONS969 958 1.2 
Income from discontinued operations, net of tax— 173 (100.0)
NET INCOME969 1,131 (14.3)
Preferred stock dividends(45)(45)— 
NET INCOME APPLICABLE TO COMMON SHAREHOLDERS$924 $1,086 (14.9)
 
BASIC EARNINGS PER SHARE
Income from Continuing Operations3.25 3.20 1.6 
Income from Discontinued Operations— 0.61 (100.0)
Basic Earnings per Share$3.25 $3.81 (14.7)
DILUTED EARNINGS PER SHARE
Income from Continuing Operations3.24 3.18 1.9 
Income from Discontinued Operations— 0.60 (100.0)
Diluted Earnings per Share$3.24 $3.78 (14.3)
AVERAGE SHARES OUTSTANDING (in thousands)
Basic284,087284,961
Diluted285,360287,202

Page 2

BECTON DICKINSON AND COMPANY
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in millions)


March 31, 2023September 30, 2022
(Unaudited) 
ASSETS
Cash and equivalents$1,981 $1,006 
Restricted cash87 153 
Short-term investments6 8 
Trade receivables, net2,413 2,191 
Inventories3,656 3,224 
Prepaid expenses and other1,444 1,559 
TOTAL CURRENT ASSETS9,587 8,141 
Property, plant and equipment, net6,356 6,012 
Goodwill and other intangibles, net36,458 36,932 
Other assets1,994 1,848 
TOTAL ASSETS$54,394 $52,934 
LIABILITIES AND SHAREHOLDERS' EQUITY
Current debt obligations$2,214 $2,179 
Other current liabilities5,090 5,632 
Long-term debt16,010 13,886 
Long-term employee benefit obligations920 902 
Deferred income taxes and other liabilities4,471 5,052 
Shareholders’ equity25,689 25,282 
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY$54,394 $52,934 


Page 3

BECTON DICKINSON AND COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited; Amounts in millions)

Six Months Ended March 31,
20232022
OPERATING ACTIVITIES
Net income $969 $1,131 
Less: Income from discontinued operations, net of tax
— 173 
Income from continuing operations, net of tax969 958 
Depreciation and amortization1,130 1,094 
Change in operating assets and liabilities and other, net(1,515)(1,231)
NET CASH PROVIDED BY CONTINUING OPERATING ACTIVITIES 584 820 
INVESTING ACTIVITIES
Capital expenditures(389)(405)
Acquisitions, net of cash acquired— (450)
Other, net(134)(124)
NET CASH USED FOR CONTINUING INVESTING ACTIVITIES(524)(979)
FINANCING ACTIVITIES
Change in short-term debt365 — 
Proceeds from long-term debt1,662 — 
Distribution from Embecta Corp.— 1,266 
Payments of debt(529)(2)
Dividends paid(563)(541)
Other, net(101)(63)
NET CASH PROVIDED BY CONTINUING FINANCING ACTIVITIES835 659 
DISCONTINUED OPERATIONS
Net cash provided by operating activities— 298 
Net cash used for investing activities— (11)
Net cash provided by financing activities— 145 
NET CASH PROVIDED BY DISCONTINUED OPERATIONS— 432 
Effect of exchange rate changes on cash and equivalents and restricted cash14 (4)
NET INCREASE IN CASH AND EQUIVALENTS AND RESTRICTED CASH909 928 
OPENING CASH AND EQUIVALENTS AND RESTRICTED CASH1,159 2,392 
CLOSING CASH AND EQUIVALENTS AND RESTRICTED CASH$2,068 $3,320 



Page 4

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS - UNITED STATES
Three Months Ended March 31,
(Unaudited; Amounts in millions)
   A  B  C=(A-B)/B
   20232022% Change
BD MEDICAL  
Medication Delivery Solutions (a)  $616 $590 4.4 
Medication Management Solutions  550 461 19.4 
Pharmaceutical Systems  173 125 38.1 
TOTAL  $1,339 $1,176 13.9 
   
BD LIFE SCIENCES  
Integrated Diagnostic Solutions$422 $618 (31.7)
Biosciences  159 129 23.3 
TOTAL  $581 $747 (22.2)
BD INTERVENTIONAL
Surgery$295 $268 10.0 
Peripheral Intervention256 240 6.5 
Urology and Critical Care263 239 10.0 
TOTAL$813 $746 8.9 
TOTAL UNITED STATES FROM CONTINUING OPERATIONS  $2,733 $2,669 2.4 
(a)Prior-period amounts were recast to reflect former intercompany transactions with Embecta.
Page 5

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS - INTERNATIONAL
Three Months Ended March 31, (continued)
(Unaudited; Amounts in millions)
      D=(A-B)/B E=(A-B-C)/B
 A  B  C % Change
 20232022FX ImpactReportedFXN
BD MEDICAL
Medication Delivery Solutions (a)$454 $460 $(28)(1.2)4.9 
Medication Management Solutions 173 143 (10)20.9 28.1 
Pharmaceutical Systems (a)394 375 (18)5.0 9.8 
TOTAL$1,022 $978 $(56)4.4 10.2 
BD LIFE SCIENCES
Integrated Diagnostic Solutions$466 $532 $(28)(12.3)(7.1)
Biosciences228 206 (12)10.3 15.9 
TOTAL$694 $738 $(40)(6.0)(0.7)
BD INTERVENTIONAL
Surgery$86 $72 $(6)19.3 27.1 
Peripheral Intervention213 210 (15)1.3 8.5 
Urology and Critical Care74 82 (7)(9.7)(1.4)
TOTAL$373 $364 $(28)2.4 10.0 
        
TOTAL INTERNATIONAL FROM CONTINUING OPERATIONS$2,088 $2,081 $(124)0.4 6.3 
(a)Prior-period amounts were recast to reflect former intercompany transactions with Embecta.
Page 6

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS - TOTAL
Three Months Ended March 31, (continued)
(Unaudited; Amounts in millions)
        D=(A-B)/B E=(A-B-C)/B
   A  B  C % Change
   20232022  FX Impact Reported FXN
BD MEDICAL             
Medication Delivery Solutions (a)  $1,070 $1,049 $(28)1.9 4.6 
Medication Management Solutions  723 604 (10)19.8 21.5 
Pharmaceutical Systems (a)  567 501 (18)13.3 16.9 
TOTAL  $2,360 $2,154 $(56)9.6 12.2 
BD LIFE SCIENCES  
Integrated Diagnostic Solutions$888 $1,150 $(28)(22.7)(20.3)
Biosciences  386 335 (12)15.3 18.7 
TOTAL  $1,275 $1,485 $(40)(14.2)(11.5)
BD INTERVENTIONAL
Surgery$381 $340 $(6)12.0 13.7 
Peripheral Intervention468 450 (15)4.1 7.5 
Urology and Critical Care336 320 (7)5.0 7.1 
TOTAL$1,186 $1,111 $(28)6.8 9.3 
   
TOTAL REVENUES FROM CONTINUING OPERATIONS  $4,821 $4,750 $(124)1.5 4.1 
(a)Prior-period amounts were recast to reflect former intercompany transactions with Embecta.

Page 7

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS - UNITED STATES
Six Months Ended March 31,
(Unaudited; Amounts in millions)
   A  B  C=(A-B)/B
   20232022  % Change
BD MEDICAL         
Medication Delivery Solutions (a)  $1,235 $1,210 2.1 
Medication Management Solutions   1,114 945 17.9 
Pharmaceutical Systems  292 228 28.2 
TOTAL  $2,642 $2,383 10.9 
 
BD LIFE SCIENCES  
Integrated Diagnostic Solutions  $930 $1,232 (24.6)
Biosciences  296 258 14.8 
TOTAL  $1,226 $1,490 (17.8)
BD INTERVENTIONAL
Surgery $582 $549 5.9 
Peripheral Intervention 492 457 7.6 
Urology and Critical Care 522 492 5.9 
TOTAL$1,595 $1,498 6.5 
          
TOTAL UNITED STATES FROM CONTINUING OPERATIONS  $5,462 $5,372 1.7 
(a)Prior-period amounts were recast to reflect former intercompany transactions with Embecta.


Page 8

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS - INTERNATIONAL
Six Months Ended March 31, (continued)
(Unaudited; Amounts in millions)
        D=(A-B)/B E=(A-B-C)/B
   A  B  C % Change
   20232022  FX Impact Reported FXN
BD MEDICAL       
Medication Delivery Solutions (a)$873 $936 $(75)(6.7)1.3 
Medication Management Solutions316 286 (28)10.3 20.3 
Pharmaceutical Systems (a)684 669 (48)2.2 9.4 
TOTAL$1,873 $1,892 $(151)(1.0)7.0 
 
BD LIFE SCIENCES
Integrated Diagnostic Solutions$911 $1,062 $(81)(14.2)(6.6)
Biosciences440 416 (31)5.9 13.4 
TOTAL$1,351 $1,478 $(113)(8.6)(1.0)
BD INTERVENTIONAL
Surgery$162 $152 $(16)6.3 16.6 
Peripheral Intervention 410 407 (40)0.8 10.7 
Urology and Critical Care 148 168 (20)(11.9)(0.2)
TOTAL$720 $727 $(75)(1.0)9.4 
        
TOTAL INTERNATIONAL FROM CONTINUING OPERATIONS$3,944 $4,096 $(339)(3.7)4.6 
(a)Prior-period amounts were recast to reflect former intercompany transactions with Embecta.


Page 9

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS - TOTAL
Six Months Ended March 31, (continued)
(Unaudited; Amounts in millions)
        D=(A-B)/B E=(A-B-C)/B
   A  B  C % Change
   20232022  FX Impact Reported FXN
BD MEDICAL             
Medication Delivery Solutions (a)  $2,109 $2,146 $(75)(1.7)1.8 
Medication Management Solutions   1,430 1,231 (28)16.1 18.4 
Pharmaceutical Systems (a)  976 897 (48)8.8 14.1 
TOTAL  $4,515 $4,274 $(151)5.6 9.2 
 
BD LIFE SCIENCES  
Integrated Diagnostic Solutions  $1,841 $2,295 $(81)(19.8)(16.2)
Biosciences  736 674 (31)9.3 13.9 
TOTAL  $2,577 $2,968 $(113)(13.2)(9.4)
BD INTERVENTIONAL
Surgery $744 $701 $(16)6.0 8.2 
Peripheral Intervention 902 863 (40)4.4 9.1 
Urology and Critical Care 670 661 (20)1.4 4.4 
TOTAL$2,315 $2,225 $(75)4.0 7.4 
              
TOTAL REVENUES FROM CONTINUING OPERATIONS  $9,407 $9,468 $(339)(0.6)2.9 
(a)Prior-period amounts were recast to reflect former intercompany transactions with Embecta.


Page 10

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
RECONCILIATION OF REPORTED REVENUE CHANGE TO BASE REVENUE CHANGE
Three Months Ended March 31,
(Unaudited; Amounts in millions)


        D=(A-B)/B E=(A-B-C)/B
   A  B  C % Change
   20232022  FX Impact Reported FXN
             
TOTAL REVENUES FROM CONTINUING OPERATIONS$4,821 $4,750 $(124)1.5 4.1 
Less: COVID-19-only Diagnostic Testing Revenues16 214 — (92.6)(92.6)
Base Revenues from Continuing Operations$4,805 $4,535 $(124)6.0 8.7 
BD LIFE SCIENCES REVENUES $1,275 $1,485 $(40)(14.2)(11.5)
Less: COVID-19-only Diagnostic Testing Revenues16 214 — (92.6)(92.6)
Base BD Life Sciences Revenues$1,259 $1,271 $(39)(0.9)2.2 
Integrated Diagnostic Solutions Revenues$888 $1,150 $(28)(22.7)(20.3)
Less: COVID-19-only Diagnostic Testing Revenues16 214 — (92.6)(92.6)
Base Integrated Diagnostic Solutions Revenues$873 $935 $(28)(6.7)(3.7)

Page 11

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
RECONCILIATION OF REPORTED REVENUE CHANGE TO BASE REVENUE CHANGE
Six Months Ended March 31,
(Unaudited; Amounts in millions)


        D=(A-B)/B E=(A-B-C)/B
   A  B  C % Change
   20232022  FX Impact Reported FXN
             
TOTAL REVENUES FROM CONTINUING OPERATIONS$9,407 $9,468 $(339)(0.6)2.9 
Less: COVID-19-only Diagnostic Testing Revenues48 399 (1)(88.0)(87.7)
Base Revenues from Continuing Operations$9,359 $9,069 $(338)3.2 6.9 
BD LIFE SCIENCES REVENUES$2,577 $2,968 $(113)(13.2)(9.4)
Less: COVID-19-only Diagnostic Testing Revenues48 399 (1)(88.0)(87.7)
Base BD Life Sciences Revenues$2,529 $2,569 $(112)(1.6)2.8 
Integrated Diagnostic Solutions Revenues$1,841 $2,295 $(81)(19.8)(16.2)
Less: COVID-19-only Diagnostic Testing Revenues48 399 (1)(88.0)(87.7)
Base Integrated Diagnostic Solutions Revenues$1,793 $1,896 $(80)(5.4)(1.2)


Page 12

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
RECONCILIATION OF REPORTED REVENUE CHANGE TO BASE ORGANIC REVENUE CHANGE
Three Months Ended March 31,
(Unaudited; Amounts in millions)

       F=(A-B)/BG=(A-B-C)/B
   A  B  CD=A-BE=A-B-C % Change
   20232022  FX ImpactReported ChangeFXN Change Reported FXN
TOTAL REVENUES FROM CONTINUING OPERATIONS  $4,821 $4,750 $(124)$71 $195 1.5 4.1
Less: COVID-19-only diagnostics16 214 — (199)(198)(92.6)(92.6)
TOTAL BASE REVENUES FROM CONTINUING OPERATIONS$4,805 $4,535 $(124)$270 $393 6.0 8.7 
Less: Inorganic revenue contribution (1)
77 77 1.7 1.7 
Total Base Organic Revenue Growth from Continuing Operations$193 $317 4.3 7.0 

(1)    Inorganic revenue contribution is defined as the amount of incremental revenue recognized during the first 12 months post-acquisition. Acquisitions include: Parata and MedKeeper in the Medical Segment, and Cytognos in the Life Sciences Segment.

Page 13

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS
(Unaudited)
 Three Months Ended March 31,
   20232022 Change Foreign
Currency
Translation		 Foreign
Currency
Neutral
Change		 Change % Foreign
Currency
Neutral
Change %
Reported Diluted Earnings per Share from Continuing Operations$1.53 $1.28 $0.25 $(0.22)$0.47 19.5%36.7%
Purchase accounting adjustments ($347 million and $356 million pre-tax, respectively) (1)
1.21 1.24 (0.01)
Integration costs ($29 million and $11 million pre-tax, respectively) (2)
0.10 0.04 — 
Restructuring costs ($33 million and $17 million pre-tax, respectively) (2)
0.11 0.06 — 
Separation-related items ($3 million pre-tax) (3)
0.01 — — 
European regulatory initiative-related costs ($37 million and $35 million pre-tax, respectively) (4)
0.13 0.12 — 
Product, litigation, and other items ($109 million pre-tax)(5)
— 0.38 — 
Income tax benefit of special items ($(70) million and $(96) million, respectively)(0.24)(0.34)— 
Adjusted Diluted Earnings per Share from Continuing Operations$2.86 $2.78 $0.08 $(0.23)$0.31 2.9%11.2%
(1)Includes amortization and other adjustments related to the purchase accounting for acquisitions.
(2)Represents costs associated with acquisition-related integration and restructuring activities, as well as costs associated with simplification and cost saving initiatives.
(3)Represents costs recorded to Other operating expense (income), net incurred in connection with the separation of BD's former Diabetes Care business.
(4)Represents costs incurred to develop processes and systems to establish initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation, which represent a significant, unusual change to the existing regulatory framework. We consider these costs to be duplicative of previously incurred costs and/or one-off costs, which are limited to a specific period of time. These expenses, which are recorded in Cost of products sold and Research and development expense, include the cost of labor, other services and consulting (in particular, research and development and clinical trials) and supplies, travel and other miscellaneous costs.
(5)Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain product liability and legal defense costs, certain investment gains and losses, and certain asset impairment charges. The amount in 2022 include charges to Cost of products sold of $35 million to adjust the estimate of future product remediation costs and $54 million related to a noncash asset impairment charge in the Medical segment.


Page 14

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS
(Unaudited)
 Six Months Ended March 31,
 20232022 ChangeForeign
Currency
Translation		Foreign
Currency
Neutral
Change		Change %Foreign
Currency
Neutral
Change %
Reported Diluted Earnings per Share from Continuing Operations$3.24 $3.18 $0.06 $(0.26)$0.32 1.9 %10.1 %
Purchase accounting adjustments ($709 million and $720 million pre-tax, respectively) (1)
2.49 2.51 (0.01)
Integration costs ($47 million and $28 million pre-tax, respectively) (2)
0.16 0.10 (0.01)
Restructuring costs ($59 million and $34 million pre-tax, respectively) (2)
0.21 0.12 — 
Separation-related items ($9 million pre-tax) (3)
0.03 — — 
European regulatory initiative-related costs ($70 million and $66 million pre-tax, respectively) (4)
0.24 0.23 — 
Product, litigation, and other items ($4 million and $131 million pre-tax, respectively) (5)
0.01 0.46 — 
Income tax benefit of special items ($(155) million and $(182) million, respectively)(0.54)(0.63)0.01 
Adjusted Diluted Earnings per Share from Continuing Operations$5.84 $5.95 $(0.11)$(0.27)$0.16 (1.8)%2.7 %
(1)Includes amortization and other adjustments related to the purchase accounting for acquisitions.
(2)Represents costs associated with acquisition-related integration and restructuring activities, as well as costs associated with simplification and cost saving initiatives.
(3)Represents costs recorded to Other operating expense (income), net incurred in connection with the separation of BD's former Diabetes Care business.
(4)Represents costs incurred to develop processes and systems to establish initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation, which represent a significant, unusual change to the existing regulatory framework. We consider these costs to be duplicative of previously incurred costs and/or one-off costs, which are limited to a specific period of time. These expenses, which are recorded in Cost of products sold and Research and development expense, include the cost of labor, other services and consulting (in particular, research and development and clinical trials) and supplies, travel and other miscellaneous costs.
(5)Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain product liability and legal defense costs, certain investment gains and losses, and certain asset impairment charges. The amount in 2022 include charges to Cost of products sold of $35 million to adjust the estimate of future product remediation costs and $54 million related to a noncash asset impairment charge in the Medical segment.
Page 15

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
FY 2023 OUTLOOK RECONCILIATION




Full Year FY2022Full Year FY2023 Outlook
($ in millions)FX Neutral % ChangeReported Revenues
BDX Reported Revenues from Continuing Operations$18,870 
Less: COVID-19-only Diagnostic Testing Revenues511 
Base Business Revenues from Continuing Operations$18,358 
FY2023 Base Business Revenue Growth+6.5% to +7.0%
FY2023 COVID-19-Only Diagnostic Testing Revenues~$50 million
Illustrative Foreign Currency (FX) Impact, based on FX spot rates(~200) basis points
Total FY 2023 Revenues from Continuing Operations$19.2 to $19.3 billion


Note - Base Business Revenues denotes total revenues less estimated revenues for COVID-19 only diagnostic testing



Page 16

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
FY 2023 OUTLOOK RECONCILIATION CONTINUED

Full Year FY2023 Outlook
Full Year FY2022 from Continuing OperationsTotal Company
Reported Diluted Earnings per Share$5.38 
Purchase accounting adjustments ($1.431 billion pre-tax) (1)
4.98 
Integration costs ($68 million pre-tax) (2)
0.24 
Restructuring costs ($123 million pre-tax) (2)
0.43 
Separation-related items ($20 million pre-tax) (3)
0.07 
European regulatory initiative-related costs ($146 million pre-tax) (4)
0.51 
Product, litigation, and other items ($268 million pre-tax) (5)
0.93 
Impacts of debt extinguishment ($24 million pre-tax)0.08 
Income tax benefit of special items ($(366) million)
(1.27)
Adjusted Diluted Earnings per Share$11.35 $12.10 to $12.32
Illustrative Foreign Currency (FX) Impact, based on FX spot rates(~270) basis points
FX Neutral % Change~+9.5% to +11.0%


(1)Includes amortization and other adjustments related to the purchase accounting for acquisitions.
(2)Represents costs associated with acquisition-related integration and restructuring activities, as well as costs associated with simplification and cost saving initiatives.
(3)Represents costs recorded to Other operating expense (income), net incurred in connection with the separation of BD's former Diabetes Care business.
(4)Represents costs incurred to develop processes and systems to establish initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation, which represent a significant, unusual change to the existing regulatory framework. We consider these costs to be duplicative of previously incurred costs and/or one-off costs, which are limited to a specific period of time. These expenses, which are recorded in Cost of products sold and Research and development expense, include the cost of labor, other services and consulting (in particular, research and development and clinical trials) and supplies, travel and other miscellaneous costs.
(5)Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain product liability and legal defense costs, certain investment gains and losses, and certain asset impairment charges. Items in 2022 included product remediation costs of $72 million recorded to Cost of products sold, certain asset impairment charges of $54 million recorded to Cost of products sold, and pension settlement costs of $73 million recorded to Other (expense) income, net.
.


Page 17
 EX-101.SCH 3 bdx-20230504.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 bdx-20230504_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 bdx-20230504_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Notes 1.900% due December 15, 2026 Notes 1.900% due December 15, 2026 [Member] Notes 1.900% due December 15, 2026 [Member] Entity Central Index Key Entity Central Index Key Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Soliciting Material Soliciting Material Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Redeemable Preferred Stock Redeemable Preferred Stock [Member] Class of Stock [Domain] Class of Stock [Domain] Notes 1.213% due February 12, 2036 Notes 1.213% due February 12, 2036 [Member] Notes 1.213% due February 12, 2036 City Area Code City Area Code Notes 0.632% due June 4, 2023 Notes 0.632% due June 4, 2023 [Member] Notes 0.632% due June 4, 2023 [Member] Entities [Table] Entities [Table] Notes 0.034% due August 13, 2025 Notes 0.034% due August 13, 2025 [Member] Notes 0.034% due August 13, 2025 Title of 12(b) Security Title of 12(b) Security Exchange [Domain] Exchange [Domain] Amendment Flag Amendment Flag Entity Information [Line Items] Entity Information [Line Items] Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Notes 1.401% due May 24, 2023 Notes 1.401% due May 24, 2023 [Member] Notes 1.401% due May 24, 2023 [Member] Notes 1.208% due June 4, 2026 Notes 1.208% due June 4, 2026 [Member] Notes 1.208% due June 4, 2026 [Member] Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Entity Tax Identification Number Entity Tax Identification Number Common Stock Common Stock [Member] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, City or Town Entity Address, City or Town Class of Stock [Axis] Class of Stock [Axis] Local Phone Number Local Phone Number Notes 0.000% due August 13, 2023 Notes 0.000% due August 13, 2023 [Member] Notes 0.000% due August 13, 2023 Written Communications Written Communications Cover [Abstract] Cover [Abstract] NEW YORK STOCK EXCHANGE, INC. NEW YORK STOCK EXCHANGE, INC. [Member] Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Notes 3.020% due May 24, 2025 Notes 3.020% due May 24, 2025 [Member] Notes 3.020% due May 24, 2025 [Member] Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 6 bdx-20230504_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 imagea.jpg GR begin 644 imagea.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover Page
May 04, 2023
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date May 04, 2023
Entity Registrant Name BECTON, DICKINSON AND COMPANY
Entity Central Index Key 0000010795
Amendment Flag false
Entity Incorporation, State or Country Code NJ
Entity File Number 001-4802
Entity Tax Identification Number 22-0760120
Entity Address, Address Line One 1 Becton Drive,
Entity Address, City or Town Franklin Lakes,
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07417-1880
City Area Code (201)
Local Phone Number 847-6800
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security Common stock, par value $1.00
Trading Symbol BDX
Security Exchange Name NYSE
Redeemable Preferred Stock | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security Depositary Shares, each representing a 1/20th interest in a share of 6.00% Mandatory Convertible Preferred Stock, Series B
Trading Symbol BDXB
Security Exchange Name NYSE
Notes 1.900% due December 15, 2026 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 1.900% Notes due December 15, 2026
Trading Symbol BDX26
Security Exchange Name NYSE
Notes 1.401% due May 24, 2023 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 1.401% Notes due May 24, 2023
Trading Symbol BDX23A
Security Exchange Name NYSE
Notes 3.020% due May 24, 2025 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 3.020% Notes due May 24, 2025
Trading Symbol BDX25
Security Exchange Name NYSE
Notes 0.632% due June 4, 2023 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 0.632% Notes due June 4, 2023
Trading Symbol BDX/23A
Security Exchange Name NYSE
Notes 1.208% due June 4, 2026 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 1.208% Notes due June 4, 2026
Trading Symbol BDX/26A
Security Exchange Name NYSE
Notes 1.213% due February 12, 2036 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 1.213% Notes due February 12, 2036
Trading Symbol BDX/36
Security Exchange Name NYSE
Notes 0.000% due August 13, 2023 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 0.000% Notes due August 13, 2023
Trading Symbol BDX23B
Security Exchange Name NYSE
Notes 0.034% due August 13, 2025 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 0.034% Notes due August 13, 2025
Trading Symbol BDX25A
Security Exchange Name NYSE

XML 9 bdx-20230504_htm.xml IDEA: XBRL DOCUMENT 0000010795 2023-05-04 2023-05-04 0000010795 us-gaap:CommonStockMember exch:XNYS 2023-05-04 2023-05-04 0000010795 us-gaap:RedeemablePreferredStockMember exch:XNYS 2023-05-04 2023-05-04 0000010795 bdx:Notes1.900dueDecember152026Member exch:XNYS 2023-05-04 2023-05-04 0000010795 bdx:Notes1.401dueMay242023Member exch:XNYS 2023-05-04 2023-05-04 0000010795 bdx:Notes3.020dueMay242025Member exch:XNYS 2023-05-04 2023-05-04 0000010795 bdx:Notes0.632dueJune42023Member exch:XNYS 2023-05-04 2023-05-04 0000010795 bdx:Notes1.208dueJune42026Member exch:XNYS 2023-05-04 2023-05-04 0000010795 bdx:Notes1213DueFebruary122036Member exch:XNYS 2023-05-04 2023-05-04 0000010795 bdx:Notes0000DueAugust132023Member exch:XNYS 2023-05-04 2023-05-04 0000010795 bdx:Notes0034DueAugust132025Member exch:XNYS 2023-05-04 2023-05-04 0000010795 false 8-K 2023-05-04 BECTON, DICKINSON AND COMPANY NJ 001-4802 22-0760120 1 Becton Drive, Franklin Lakes, NJ 07417-1880 (201) 847-6800 false false false false Common stock, par value $1.00 BDX NYSE Depositary Shares, each representing a 1/20th interest in a share of 6.00% Mandatory Convertible Preferred Stock, Series B BDXB NYSE 1.900% Notes due December 15, 2026 BDX26 NYSE 1.401% Notes due May 24, 2023 BDX23A NYSE 3.020% Notes due May 24, 2025 BDX25 NYSE 0.632% Notes due June 4, 2023 BDX/23A NYSE 1.208% Notes due June 4, 2026 BDX/26A NYSE 1.213% Notes due February 12, 2036 BDX/36 NYSE 0.000% Notes due August 13, 2023 BDX23B NYSE 0.034% Notes due August 13, 2025 BDX25A NYSE false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 11 22 1 false 11 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.bd.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports bdx-20230504.htm bdx-20230504.xsd bdx-20230504_def.xml bdx-20230504_lab.xml bdx-20230504_pre.xml ex99103312023.htm http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bdx-20230504.htm": { "axisCustom": 0, "axisStandard": 2, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 49 }, "contextCount": 11, "dts": { "definitionLink": { "local": [ "bdx-20230504_def.xml" ] }, "inline": { "local": [ "bdx-20230504.htm" ] }, "labelLink": { "local": [ "bdx-20230504_lab.xml" ] }, "presentationLink": { "local": [ "bdx-20230504_pre.xml" ] }, "schema": { "local": [ "bdx-20230504.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd" ] } }, "elementCount": 40, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 8, "memberStandard": 3, "nsprefix": "bdx", "nsuri": "http://www.bd.com/20230504", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdx-20230504.htm", "contextRef": "i807ceea6342049d79f405825c2982325_D20230504-20230504", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.bd.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdx-20230504.htm", "contextRef": "i807ceea6342049d79f405825c2982325_D20230504-20230504", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 11, "tag": { "bdx_Notes0.632dueJune42023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes 0.632% due June 4, 2023 [Member]", "label": "Notes 0.632% due June 4, 2023 [Member]", "terseLabel": "Notes 0.632% due June 4, 2023" } } }, "localname": "Notes0.632dueJune42023Member", "nsuri": "http://www.bd.com/20230504", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "bdx_Notes0000DueAugust132023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes 0.000% due August 13, 2023", "label": "Notes 0.000% due August 13, 2023 [Member]", "terseLabel": "Notes 0.000% due August 13, 2023" } } }, "localname": "Notes0000DueAugust132023Member", "nsuri": "http://www.bd.com/20230504", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "bdx_Notes0034DueAugust132025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes 0.034% due August 13, 2025", "label": "Notes 0.034% due August 13, 2025 [Member]", "terseLabel": "Notes 0.034% due August 13, 2025" } } }, "localname": "Notes0034DueAugust132025Member", "nsuri": "http://www.bd.com/20230504", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "bdx_Notes1.208dueJune42026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes 1.208% due June 4, 2026 [Member]", "label": "Notes 1.208% due June 4, 2026 [Member]", "terseLabel": "Notes 1.208% due June 4, 2026" } } }, "localname": "Notes1.208dueJune42026Member", "nsuri": "http://www.bd.com/20230504", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "bdx_Notes1.401dueMay242023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes 1.401% due May 24, 2023 [Member]", "label": "Notes 1.401% due May 24, 2023 [Member]", "terseLabel": "Notes 1.401% due May 24, 2023" } } }, "localname": "Notes1.401dueMay242023Member", "nsuri": "http://www.bd.com/20230504", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "bdx_Notes1.900dueDecember152026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes 1.900% due December 15, 2026 [Member]", "label": "Notes 1.900% due December 15, 2026 [Member]", "terseLabel": "Notes 1.900% due December 15, 2026" } } }, "localname": "Notes1.900dueDecember152026Member", "nsuri": "http://www.bd.com/20230504", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "bdx_Notes1213DueFebruary122036Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes 1.213% due February 12, 2036", "label": "Notes 1.213% due February 12, 2036 [Member]", "terseLabel": "Notes 1.213% due February 12, 2036" } } }, "localname": "Notes1213DueFebruary122036Member", "nsuri": "http://www.bd.com/20230504", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "bdx_Notes3.020dueMay242025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes 3.020% due May 24, 2025 [Member]", "label": "Notes 3.020% due May 24, 2025 [Member]", "terseLabel": "Notes 3.020% due May 24, 2025" } } }, "localname": "Notes3.020dueMay242025Member", "nsuri": "http://www.bd.com/20230504", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]", "terseLabel": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.", "label": "Exchange [Domain]", "terseLabel": "Exchange [Domain]" } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]", "terseLabel": "NEW YORK STOCK EXCHANGE, INC." } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_RedeemablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redeemable Preferred Stock [Member]", "terseLabel": "Redeemable Preferred Stock" } } }, "localname": "RedeemablePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0000010795-23-000038-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000010795-23-000038-xbrl.zip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end